Payment overview · 2025
General Payments
$782.29
38 reported records · 14 companies
Healthcare provider profile · identity verified
Kevin T Jackson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HARRISON, AR · NPI 1144291907
Verified facts
What the public records show
CMS Open Payments records show Kevin T Jackson, M.D. received $782.29 in general payments during 2025 across 38 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 18.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Kerendia, Nurtec Odt, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Kerendia by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 243 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $147.01 | 18.8% | 8 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $99.67 | 12.7% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $87.21 | 11.2% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $76.02 | 9.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $69.50 | 8.9% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $56.53 | 7.2% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $56.49 | 7.2% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $34.70 | 4.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.94 | 4.3% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $31.67 | 4.0% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $28.01 | 3.6% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $24.41 | 3.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.96 | 2.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.17 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $782.29 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $147.01 | 8 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $99.67 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $76.02 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $60.37 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $56.53 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $54.28 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $54.28 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $41.09 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $34.70 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $31.67 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $28.01 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $26.84 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $24.41 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.96 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.38 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.40 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 131 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 88 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 243 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
88 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
45 | 12 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
243 | 39 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
131 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 796 | 152 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 621 | 96 |
| Omeprazole | Omeprazole | 568 | 114 |
| Lisinopril | Lisinopril | 535 | 100 |
| Atorvastatin Calcium | Atorvastatin Calcium | 534 | 111 |
| Alprazolam | Alprazolam | 472 | 74 |
| Furosemide | Furosemide | 368 | 88 |
| Trazodone Hcl | Trazodone Hcl | 340 | 56 |
| Gabapentin | Gabapentin | 325 | 65 |
| Losartan Potassium | Losartan Potassium | 317 | 64 |
| Tramadol Hcl | Tramadol Hcl | 313 | 58 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 302 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 299 | 65 |
| Potassium Chloride | Potassium Chloride | 285 | 65 |
| Amlodipine Besylate | Amlodipine Besylate | 277 | 72 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 271 | 51 |
| Zolpidem Tartrate | Zolpidem Tartrate | 268 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 267 | 72 |
| Meloxicam | Meloxicam | 262 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 261 | 64 |
| Ozempic | Semaglutide | 243 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 222 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 217 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 209 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 198 | 37 |
| Metformin Hcl | Metformin Hcl | 186 | 49 |
| Azithromycin | Azithromycin | 166 | 110 |
| Atenolol | Atenolol | 162 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 162 | 38 |
| Cephalexin | Cephalexin | 161 | 81 |
| Mounjaro | Tirzepatide | 161 | 31 |
| Carvedilol | Carvedilol | 158 | 35 |
| Fluoxetine Hcl | Fluoxetine Hcl | 158 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 155 | 26 |
| Simvastatin | Simvastatin | 149 | 28 |
| Sertraline Hcl | Sertraline Hcl | 147 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 145 | 32 |
| Tizanidine Hcl | Tizanidine Hcl | 139 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 136 | 27 |
| Oxycodone Hcl | Oxycodone Hcl | 136 | 17 |
| Pregabalin | Pregabalin | 135 | 28 |
| Ropinirole Hcl | Ropinirole Hcl | 134 | 22 |
| Bupropion Xl | Bupropion Hcl | 133 | 19 |
| Diazepam | Diazepam | 131 | 30 |
| Eliquis | Apixaban | 131 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 130 | 37 |
| Allopurinol | Allopurinol | 126 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 121 | 23 |
| Clonazepam | Clonazepam | 113 | 18 |
| Trintellix | Vortioxetine Hydrobromide | 112 | 11 |
| Jardiance | Empagliflozin | 110 | 21 |
| Temazepam | Temazepam | 110 | 16 |
| Xarelto | Rivaroxaban | 110 | 14 |
| Montelukast Sodium | Montelukast Sodium | 107 | 20 |
| Lorazepam | Lorazepam | 103 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 103 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 100 | 19 |
| Methocarbamol | Methocarbamol | 98 | 30 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 96 | 15 |
| Sucralfate | Sucralfate | 96 | 27 |
| Famotidine | Famotidine | 95 | 26 |
| Memantine Hcl | Memantine Hcl | 93 | 15 |
| Alendronate Sodium | Alendronate Sodium | 92 | 24 |
| Farxiga | Dapagliflozin Propanediol | 88 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 88 | 21 |
| Ventolin Hfa | Albuterol Sulfate | 87 | 19 |
| Celecoxib | Celecoxib | 86 | 17 |
| Fluconazole | Fluconazole | 83 | 40 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 81 | 42 |
| Amitriptyline Hcl | Amitriptyline Hcl | 76 | 18 |
| Estradiol | Estradiol | 76 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 75 | 14 |
| Spironolactone | Spironolactone | 75 | 22 |
| Doxazosin Mesylate | Doxazosin Mesylate | 73 | 16 |
| Methylprednisolone | Methylprednisolone | 73 | 56 |
| Paroxetine Hcl | Paroxetine Hcl | 72 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 69 | 17 |
| Tresiba Flextouch U-200 | Insulin Degludec | 67 | suppressed |
| Amoxicillin | Amoxicillin | 63 | 45 |
| Donepezil Hcl | Donepezil Hcl | 62 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 62 | 26 |
| Prednisone | Prednisone | 59 | 30 |
| Buspirone Hcl | Buspirone Hcl | 57 | 13 |
| Finasteride | Finasteride | 56 | 15 |
| Glimepiride | Glimepiride | 55 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 55 | 19 |
| Carisoprodol | Carisoprodol | 53 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 53 | 11 |
| Warfarin Sodium | Warfarin Sodium | 53 | suppressed |
| Aripiprazole | Aripiprazole | 51 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 51 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 51 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 50 | 12 |
| Eszopiclone | Eszopiclone | 49 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 49 | 16 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 48 | 11 |
| Bumetanide | Bumetanide | 46 | suppressed |
| Belsomra | Suvorexant | 45 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 45 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 43 | 19 |
| Ibuprofen | Ibuprofen | 43 | 12 |
| Mirtazapine | Mirtazapine | 43 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 42 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 42 | suppressed |
| Olanzapine | Olanzapine | 41 | suppressed |
| Ondansetron Odt | Ondansetron | 41 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 38 | 22 |
| Acyclovir | Acyclovir | 37 | 16 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 37 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 37 | suppressed |
| Lacosamide | Lacosamide | 36 | suppressed |
| Propylthiouracil | Propylthiouracil | 36 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 36 | 25 |
| Testosterone Cypionate | Testosterone Cypionate | 36 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Baclofen | Baclofen | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 35 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 35 | suppressed |
| Valsartan | Valsartan | 35 | suppressed |
| Verapamil Er | Verapamil Hcl | 35 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 34 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 34 | suppressed |
| Nitroglycerin | Nitroglycerin | 34 | 20 |
| Promethazine Hcl | Promethazine Hcl | 34 | 11 |
| Lansoprazole | Lansoprazole | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Naproxen | Naproxen | 33 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Lamotrigine | Lamotrigine | 32 | suppressed |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 32 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 32 | suppressed |
| Ezetimibe | Ezetimibe | 31 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 15 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 21 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 28 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | 12 |
| Linzess | Linaclotide | 28 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 28 | suppressed |
| Trimethoprim | Trimethoprim | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Cefdinir | Cefdinir | 24 | 21 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 20 |
| Colesevelam Hcl | Colesevelam Hcl | 23 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Febuxostat | Febuxostat | 22 | suppressed |
| Oxycontin | Oxycodone Hcl | 22 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 22 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 21 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Nystatin | Nystatin | 21 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 17 |
| Glipizide | Glipizide | 19 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Premarin | Estrogens, Conjugated | 19 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 19 | suppressed |
| Aristada | Aripiprazole Lauroxil | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 17 | 15 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 15 | suppressed |
| Movantik | Naloxegol Oxalate | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 13 | 13 |
| Cartia Xt | Diltiazem Hcl | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Ubrelvy | Ubrogepant | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Dexilant | Dexlansoprazole | 12 | suppressed |
| Dulera | Mometasone/Formoterol | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Levetiracetam Er | Levetiracetam | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Mesalamine Er | Mesalamine | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Savella | Milnacipran Hcl | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Sulfasalazine | Sulfasalazine | 12 | suppressed |
| Zaleplon | Zaleplon | 12 | suppressed |
| Adcirca | Tadalafil | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $782.29 · 38 records | Bayer Healthcare Pharmaceuticals Inc. | ABRYSVO, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, Kerendia, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, Senza, VOQUEZNA, VRAYLAR, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error